OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) today announced the online publication in BioRxiv of positive data from preclinical and human ex vivo studies with CoVepiT, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback